Status:
COMPLETED
Electrode Positions in Cardioverting Atrial Fibrillation
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Regionshospitalet Viborg, Skive
Randers Regional Hospital
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Atrial fibrillation is the most common heart rhythm disorder, and the incidence is rapidly increasing. Cardioversion using an electrical shock (DC-cardioversion) is an important treatment to reduce sy...
Eligibility Criteria
Inclusion
- Atrial fibrillation (documented on an ECG-12)
- Able and willing to sign informed consent
- Age ≥ 18 years
- Anticoagulation according to guidelines (Patients with atrial fibrillation for \>48 hours will be required to have a documented weekly international normalized ratio (INR) ≥2.0 (including within 48 hours of cardioversion) or treatment with non-vitamin K oral anticoagulant for three weeks or longer. Alternatively, a transoesophageal echocardiogram documenting the absence of intracardiac thrombi is accepted and cardioversion can be performed on treatment with low molecular weight heparin).
Exclusion
- Implanted pacemaker and/or cardioverter defibrillator (ICD)
- Prior enrollment in the trial
- Hemodynamically unstable atrial fibrillation
- Untreated hyperthyroidism
- Known or suspected pregnancy
Key Trial Info
Start Date :
February 19 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 2 2020
Estimated Enrollment :
468 Patients enrolled
Trial Details
Trial ID
NCT03817372
Start Date
February 19 2019
End Date
October 2 2020
Last Update
October 8 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Horsens Regional Hospital
Horsens, Denmark, 8700
2
Randers Regional Hospital
Randers, Denmark, 8930
3
Viborg Regional Hospital
Viborg, Denmark, 8800